Fuji Pharma Co., Ltd. (FRA:FUP)

Fuji Pharma Statistics

Total Valuation

Fuji Pharma has a market cap or net worth of EUR 254.30 million. The enterprise value is 383.16 million.

Market Cap	254.30M
Enterprise Value	383.16M

Important Dates

The next estimated earnings date is Thursday, February 5, 2026.

Earnings Date	Feb 5, 2026
Ex-Dividend Date	Sep 29, 2025

Share Statistics

Current Share Class	24.46M
Shares Outstanding	n/a
Shares Change (YoY)	+0.38%
Shares Change (QoQ)	+0.24%
Owned by Insiders (%)	41.40%
Owned by Institutions (%)	13.92%
Float	11.66M

Valuation Ratios

The trailing PE ratio is 14.72.

PE Ratio	14.72
Forward PE	n/a
PS Ratio	0.85
PB Ratio	0.94
P/TBV Ratio	1.34
P/FCF Ratio	11.56
P/OCF Ratio	7.61
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.87, with an EV/FCF ratio of 17.42.

EV / Earnings	22.18
EV / Sales	1.36
EV / EBITDA	7.87
EV / EBIT	14.12
EV / FCF	17.42

Financial Position

The company has a current ratio of 1.55, with a Debt / Equity ratio of 0.66.

Current Ratio	1.55
Quick Ratio	0.82
Debt / Equity	0.66
Debt / EBITDA	3.45
Debt / FCF	8.10
Interest Coverage	15.12

Financial Efficiency

Return on equity (ROE) is 6.49% and return on invested capital (ROIC) is 4.09%.

Return on Equity (ROE)	6.49%
Return on Assets (ROA)	3.40%
Return on Invested Capital (ROIC)	4.09%
Return on Capital Employed (ROCE)	7.99%
Revenue Per Employee	169,102
Profits Per Employee	9,817
Employee Count	1,760
Asset Turnover	0.56
Inventory Turnover	1.58

Taxes

In the past 12 months, Fuji Pharma has paid 5.76 million in taxes.

Income Tax	5.76M
Effective Tax Rate	25.00%

Stock Price Statistics

The stock price has increased by +10.16% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+10.16%
50-Day Moving Average	9.50
200-Day Moving Average	8.54
Relative Strength Index (RSI)	61.70
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Fuji Pharma had revenue of EUR 297.62 million and earned 17.28 million in profits. Earnings per share was 0.71.

Revenue	297.62M
Gross Profit	119.58M
Operating Income	28.74M
Pretax Income	23.04M
Net Income	17.28M
EBITDA	51.57M
EBIT	28.74M
Earnings Per Share (EPS)	0.71

Balance Sheet

The company has 41.73 million in cash and 178.17 million in debt, with a net cash position of -136.45 million.

Cash & Cash Equivalents	41.73M
Total Debt	178.17M
Net Cash	-136.45M
Net Cash Per Share	n/a
Equity (Book Value)	270.14M
Book Value Per Share	11.05
Working Capital	97.47M

Cash Flow

In the last 12 months, operating cash flow was 33.41 million and capital expenditures -11.41 million, giving a free cash flow of 22.00 million.

Operating Cash Flow	33.41M
Capital Expenditures	-11.41M
Free Cash Flow	22.00M
FCF Per Share	n/a

Margins

Gross margin is 40.18%, with operating and profit margins of 9.66% and 5.81%.

Gross Margin	40.18%
Operating Margin	9.66%
Pretax Margin	7.74%
Profit Margin	5.81%
EBITDA Margin	17.33%
EBIT Margin	9.66%
FCF Margin	7.39%

Dividends & Yields

This stock pays an annual dividend of 0.27, which amounts to a dividend yield of 2.61%.

Dividend Per Share	0.27
Dividend Yield	2.61%
Dividend Growth (YoY)	2.87%
Years of Dividend Growth	2
Payout Ratio	34.53%
Buyback Yield	-0.38%
Shareholder Yield	2.23%
Earnings Yield	6.79%
FCF Yield	8.65%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on June 27, 2018. It was a forward split with a ratio of 2.

Last Split Date	Jun 27, 2018
Split Type	Forward
Split Ratio	2

Scores

Fuji Pharma has an Altman Z-Score of 1.93 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.93
Piotroski F-Score	7